A Retrospective, Multicenter and Observational Study of Nivolumab Monotherapy Treatment in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV NSCLC Within the Expanded Access Program (EAP) in SPAIN
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NIVEX
- 12 Nov 2018 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 Planned End Date changed from 15 Sep 2018 to 15 Oct 2018.
- 08 Aug 2018 Planned End Date changed from 15 May 2018 to 15 Sep 2018.